Gsa Capital Partners LLP Galectin Therapeutics Inc Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 21,534 shares of GALT stock, worth $34,023. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,534Holding current value
$34,023% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding GALT
# of Institutions
112Shares Held
9.93MCall Options Held
3.78MPut Options Held
5.27M-
Vanguard Group Inc Valley Forge, PA2.14MShares$3.38 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.47 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.87 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA871KShares$1.38 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$629,4300.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $93.9M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...